The rate of depression in the general population is estimated as high as 15% and is at least two to three times more common in patients with cancer. Due to the complexity and constraints of cancer care, depression is often under-recognised and under-treated. Antidepressants are the most commonly used medications, however among cancer patients there are few randomised trials comparing antidepressants to placebo. Mirtazapine is an effective antidepressant with unique and special mechanism of action characterised by high response and remission rates, relatively early onset of action and favourable side-effect profile. Several studies reported that mirtazapine has a receptor-binding profile that may be suitable for use in controlling appetite loss and nausea of cancer patients. We conducted a review of the literature on the use of mirtazapine in cancer patients. We evaluated the effectiveness of mirtazapine for the management of depressive and anxiety symptoms and for several distressing symptoms such as pain, nausea, appetite loss, and sleep disturbances.
Impiego di Mirtazapina in pazienti oncologici / Pasquini, M; Berardelli, I; Cabra, A.. - In: CLINICAL MANAGEMENT ISSUES. - ISSN 2283-3137. - STAMPA. - 3:4(2010), pp. 91-95.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Impiego di Mirtazapina in pazienti oncologici|
|Data di pubblicazione:||2010|
|Citazione:||Impiego di Mirtazapina in pazienti oncologici / Pasquini, M; Berardelli, I; Cabra, A.. - In: CLINICAL MANAGEMENT ISSUES. - ISSN 2283-3137. - STAMPA. - 3:4(2010), pp. 91-95.|
|Appartiene alla tipologia:||01a Articolo in rivista|